Showing 1,096 results

Filters Content type: News, Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

UK health services

Hep C: An end in sight?

Editor's pick
Drink & Drug News
5 October 2017
Access to healthcare

Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment

Editor's pick
Kaiser Health News
5 October 2017
Pharmaceutical industry

The Hepatitis Drug Market Is Worse Than Wall Street Realises

Editor's pick
Bloomberg
4 October 2017
Hepatitis C treatment

VA models provide guidance for care of hepatitis C infection

Editor's pick
Medical Xpress
28 September 2017
Access to healthcare

No, there isn’t a hepatitis cure ‘for hipsters’ with a £35,000 price tag and own clothing line

Editor's pick
Metro
27 September 2017
Hepatitis C treatment

High prices of DAAs mean there's been little progress towards achieving WHO target of eliminating HCV by 2030

News
15 September 2017
Hepatitis C treatment

Injection drug users with HCV in Scotland lack awareness of DAA efficacy

Editor's pick
Healio
12 September 2017
Hepatitis C treatment

The availability of direct-acting antivirals is reducing disparities in the uptake of hepatitis C treatment

News
30 August 2017
Hepatitis C treatment

Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment

News
10 August 2017
Pharmaceutical industry

AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance

Editor's pick
Bloomberg
7 August 2017
New & experimental hepatitis C treatment

European and US regulators approve AbbVie's new combo for all hepatitis C genotypes

News
7 August 2017
Hepatitis C treatment

Direct-acting antivirals successfully treating hepatitis C, says Public Health England

Editor's pick
Pharmaceutical Journal
2 August 2017
Hepatitis C treatment

Australia leads the world in hepatitis C treatment – what's behind its success?

Editor's pick
The Conversation AU
31 July 2017
Hepatitis C treatment

Substantial fall in Hepatitis C rates in Canberra's jail with new treatments

Editor's pick
The Canberra Times
31 July 2017
Hepatitis C treatment

Hepatitis C patients unable to get drugs due to funding problems

Editor's pick
Irish Times
31 July 2017
Hepatitis C treatment

From chronic to cured: could Australia be the first country in the world to eliminate hep C?

Editor's pick
Kirby Institute
28 July 2017
New & experimental hepatitis C treatment

Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection

News
26 July 2017
Hepatitis C treatment

Hepatitis C treatment is effective and feasible in Africa

News
25 July 2017
Hepatitis C treatment

Curing hepatitis C improves diabetes control

News
6 July 2017
Hepatitis C treatment

Australian NSP Survey National Data Report 2012 – 2016

Editor's pick
Kirby Institute
4 July 2017
Hepatitis C treatment

Charity calls for new focus to combat Hep C infections in Scotland

Editor's pick
BBC
27 June 2017
Hepatitis C treatment

Swiss hepatitis C sufferers to get full access to expensive drug

Editor's pick
swissinfo.ch
26 June 2017
New & experimental hepatitis C treatment

New pangenotypic hepatitis C drug combinations recommended for approval in the European Union

News
26 June 2017
New & experimental hepatitis C treatment

European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes

Editor's pick
Gilead press release
26 June 2017